VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
VREX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
VREXVarex Imaging Corporation
$10.74$452M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksVREXBalance Sheet

Varex Imaging Corporation (VREX) Balance Sheet

12Y historyFree accessUpdated daily

The company's financial stability is under pressure as the equity base contracted to $474.2 million in 2026Q2, accompanied by a declining cash position of $85.3 million.

VREX Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMOct'25Sep'24Sep'23Sep'22Sep'21Sep'20Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14
Total Current Assets625.6M641.8M649.9M658.3M609.9M554.2M522M440.3M458.1M495.3M359.9M316.1M270.6M
Cash & Short-Term Investments88.3M155.1M200.5M193.9M89.4M144.6M100.6M29.9M51.9M83.3M36.5M20.6M500K
Cash Only85.3M145M168.7M152.6M89.4M144.6M100.6M29.9M51.9M83.3M36.5M20.6M500K
Short-Term Investments3M10.1M31.8M41.3M000000000
Accounts Receivable148.9M157.4M157.7M164.3M173.3M155.3M123.8M141M154M163.6M122.2M117.8M128.7M
Days Sales Outstanding62.8568.0270.9767.1373.669.2961.265.9372.6885.5471.936868.56
Inventory346.7M299.4M264.8M277.5M303.2M224.8M271.9M250.3M235.1M234.5M197.4M174.9M139.6M
Days Inventory Outstanding203.83197.22174.43167.94192.17150.11181.07174.38165.18192.52193.84167.25125.32
Other Current Assets41.7M29.9M26.9M22.6M2.1M00-200K17.1M0000
Total Non-Current Assets463.8M465.6M567.1M591.3M574.5M593.3M617.5M600.5M530.4M544.8M262.5M267.5M162.5M
Property, Plant & Equipment192.4M187.2M181.7M172.6M164.5M164.5M172.9M142.3M144.9M148.3M108.9M96.2M63M
Fixed Asset Turnover4.60x4.51x4.46x5.18x5.22x4.97x4.27x5.49x5.34x4.71x5.69x6.57x10.88x
Goodwill197.8M198.4M291M288.5M284.5M292.2M293.1M290.8M243.6M241.9M74.7M74.7M36M
Intangible Assets13.2M14M16.1M22.4M33.6M50.7M67.5M86.3M73.8M91.3M20.7M24M4.7M
Long-Term Investments97M26.6M26.8M30.4M46.4M49.3M51.3M53.6M51M52.3M49.3M58.7M49.7M
Other Non-Current Assets35.1M36.5M46.8M36.1M43.2M32.6M32.2M27.5M-6.1M-18.5M3.4M3.4M0
Total Assets1.09B1.11B1.22B1.25B1.18B1.15B1.14B1.04B988.5M1.04B622.4M583.6M433.1M
Asset Turnover0.79x0.76x0.67x0.71x0.73x0.71x0.65x0.75x0.78x0.67x1.00x1.08x1.58x
Asset Growth %-60.65%-9.01%-2.61%5.5%3.22%0.7%9.48%5.29%-4.96%67.11%6.65%34.75%-
Total Current Liabilities195.3M187.2M195.9M162.8M173.1M166.6M160.6M175.1M152.6M151.8M77.8M78.6M68.8M
Accounts Payable96.4M69.9M59.1M64.7M78.2M58.8M72.9M58.2M66.3M58.9M41.9M49.7M41.8M
Days Payables Outstanding50.5946.0438.9339.1649.5639.2648.5540.5546.5848.3541.1447.5337.52
Short-Term Debt23.7M6.3M46.3M5.4M2.1M2.8M2.5M30.7M25M20M000
Deferred Revenue (Current)54.5M13M7.9M17.4M14.2M9.1M8.6M10.5M13.2M10.5M12M9.3M3.9M
Other Current Liabilities29.3M49.3M40.5M28.6M7.9M37.3M31.7M32.9M19.1M23.2M10.3M9M13.2M
Current Ratio3.20x3.43x3.32x4.04x3.52x3.33x3.25x2.51x3.00x3.26x4.63x4.02x3.93x
Quick Ratio1.43x1.83x1.97x2.34x1.77x1.98x1.56x1.09x1.46x1.72x2.09x1.80x1.90x
Cash Conversion Cycle216.09219.2206.47195.91216.21180.14193.73199.77191.28229.7224.63187.72156.35
Total Non-Current Liabilities406M433.6M471.9M505.8M464.6M484.4M513.1M405.9M396.5M498.1M8.3M9.4M5M
Long-Term Debt329M366M397.1M441.1M412.3M431.7M452.8M364.4M364.8M463.9M000
Capital Lease Obligations106.3M29.6M23M23.3M18.1M18.7M23.1M000000
Deferred Tax Liabilities19.4M5.5M1.4M0500K2.2M2.3M9M23.2M29.5M3M3.8M0
Other Non-Current Liabilities42.9M32.5M50.4M19.7M12.3M31.8M34.9M32.5M8.5M4.7M5.3M5.6M5M
Total Liabilities601.3M620.8M667.8M668.6M637.7M651M673.7M581M549.1M649.9M86.1M88M73.8M
Total Debt381M401.9M470.4M469.8M436.4M459.4M484.5M395.1M389.8M483.9M000
Net Debt295.7M256.9M301.7M317.2M347M314.8M383.9M365.2M337.9M400.6M-36.5M-20.6M-500K
Debt / Equity0.78x0.83x0.86x0.81x0.80x0.93x1.04x0.86x0.89x1.24x---
Debt / EBITDA-90.71x-7.44x4.26x3.58x4.12x83.53x8.34x4.50x4.36x---
Net Debt / EBITDA-70.40x-4.77x2.88x2.85x2.83x66.19x7.70x3.90x3.61x-0.29x-0.15x-0.00x
Interest Coverage-0.62x-0.67x1.02x2.10x1.97x1.55x-1.54x2.02x2.18x7.08x57.42x106.25x195.56x
Total Equity488.1M486.6M549.2M581M546.7M496.5M465.8M459.8M439.4M390.2M536.3M495.6M359.3M
Equity Growth %-57.41%-11.4%-5.47%6.27%10.11%6.59%1.3%4.64%12.61%-27.24%8.21%37.93%-
Book Value per Share11.6511.7513.4611.5513.1412.3212.0111.9111.4410.2713.9712.919.36
Total Shareholders' Equity474.2M472.6M535.1M567.7M533.4M483.3M451.7M446M426.2M379M526M484.6M359.3M
Common Stock400K400K400K400K400K400K400K400K400K400K526M484.7M359.3M
Retained Earnings-11.7M-5.9M70.4M118.1M63.8M33.5M16.9M75.5M62.4M35.1M526M00
Treasury Stock0000000000000
Accumulated OCI-5.6M-5.2M-2.9M-1.2M100K0800K-1.7M5.8M800K0-100K0
Minority Interest13.9M14M14.1M13.3M13.3M13.2M14.1M13.8M13.2M11.2M10.3M11M0

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Geopolitical and competitive margin pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Eroding Equity Base and Stability

According to recent financial filings, Varex's equity base has contracted from $581.2 million in 2024Q3 to $474.2 million by 2026Q2, reflecting a weakening balance sheet trajectory as the company struggles to maintain profitability while navigating a volatile and increasingly competitive global medical imaging component market.

The consistent decline in retained earnings, which shifted from a positive $120.4 million in 2024Q3 to a negative $11.7 million in 2026Q2, suggests that the firm is currently consuming capital rather than generating it. This trend warrants close monitoring, as it indicates that the business model may be facing structural headwinds that are eroding shareholder value over time.

Leverage Management Amidst Operational Strain

Based on reported figures, Varex maintains a debt-to-equity ratio of 0.78 as of 2026Q2, which, while appearing manageable, must be viewed in the context of the company's recent inability to sustain positive net income, potentially limiting its future financial flexibility and capacity for strategic investment.

While the debt load has been reduced from its 2025 peak of $601.6 million, the persistence of negative net margins suggests that the company's leverage is not currently supported by robust cash flow generation. Investors should consider whether this debt level remains appropriate if the current operating environment continues to pressure the firm's bottom line.

Liquidity Buffer Facing Potential Compression

As reported in quarterly statements, Varex's cash position has declined from $205.1 million in 2025Q2 to $85.3 million in 2026Q2, signaling a tightening liquidity buffer that may leave the company with less room to maneuver during periods of unexpected operational volatility or supply chain disruption.

Although the current ratio remains healthy at 3.20, the rapid depletion of cash reserves suggests that the company is burning through its liquid assets to fund operations or debt service. This trend may indicate that the firm's internal cash generation is insufficient to cover its current capital requirements.

Goodwill Impairment and Asset Quality

Based on SEC filings, the reduction in goodwill from $290.4 million in 2024Q1 to $197.8 million in 2026Q2 suggests that the company has been actively adjusting its asset valuations, which may reflect management's acknowledgment of changing market realities and the potential obsolescence of previously acquired business units.

The significant write-down of intangible assets warrants further investigation, as it may signal that the competitive moat surrounding certain product lines is not as durable as previously assumed. Analysts should monitor whether further impairments are necessary if the company fails to regain its competitive footing in the high-end imaging market.

VREX — Frequently Asked Questions

Quick answers to the most common questions about buying VREX stock.

What are the total assets of Varex Imaging Corporation (VREX)?

As of 2025, Varex Imaging Corporation (VREX) had total assets of $1.11B including $641.8M in current assets.

How much debt does Varex Imaging Corporation (VREX) have?

Varex Imaging Corporation (VREX) carries total debt of $401.9M, offset by $155.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Varex Imaging Corporation?

Varex Imaging Corporation (VREX) has total shareholders' equity (book value) of $472.6M ($11.75 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Varex Imaging Corporation's current ratio and liquidity?

Varex Imaging Corporation (VREX) reported a current ratio of 3.43x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.